Condition: Neoplasms · Sponsor: Johnson & Johnson Enterprise Innovation Inc.
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| NYU Langone Health | New York, New York, United States | Recruiting |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Suspended |
| UPMC Cancer Centers | Pittsburgh, Pennsylvania, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Toronto General Hospital | Toronto, Ontario, Canada | Recruiting |
| Centre Hospitalier de l'Universite de Montreal | Montreal, Quebec, Canada | Recruiting |
| Gustave Roussy | Villejuif, France | Recruiting |
| Hosp Univ Vall D Hebron | Barcelona, Spain | Recruiting |
| Hosp Univ Fund Jimenez Diaz | Madrid, Spain | Recruiting |
| Hosp Univ Hm Sanchinarro | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06311578